Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
To date, tirzepatide has demonstrated CV safety when compared with pooled comparators in a meta-analysis of phase 2 and phase 3 studies with the hazard ratio of 0.80 (95% CI: 0.571.11) for MACE-4 [24]
Read more about our online consultation process
273 (3 Pt 1), G621G627 (1997)
10.1016/j.phrs.2019.104321 Pharmacol
Methods: We collected plasma samples and clinical data from 494 individuals with hyperlipidemia
US$ 27.48
US$ 26.16
US$ 25.09
US$ 27.58
US$ 28.99
US$ 29.40
US$ 24.32
US$ 29.34
US$ 22.44
US$ 21.82
.webp)
US$ 23.23
US$ 20.60
US$ 28.19
